Topic:

Venture Capital

Latest Headlines

Latest Headlines

Women's health biotech Forendo raises $15M from some pharma giants

Finland's Forendo Pharma has pulled in €12 million ($15.2 million) to advance its treatment for a painful uterine condition, drawing the support of a few major drugmakers.

Pfizer, Novartis chip in on $17M round for an Atlas upstart focused on pain

The busy partners at Atlas Venture have gathered together a $17 million Series A for their latest biotech creation: Quartet Medicine, which pairs together two scientific founders who have been exploring the frontiers of pain management. This is Atlas' fourth maiden round for one of their biotech launches in a little more than a week, with Cambridge, MA-based Quartet joining Unum, Raze and Bicycle in a rare streak of startups. And there are likely some more to come.

Meet Unum, a new immunotherapy biotech with Fidelity, Atlas and Sanofi in its corner

As the promise of harnessing the immune system to fight cancer grabs headlines around the industry, venture stalwarts Fidelity Biosciences and Atlas Venture have teamed up to launch Unum Therapeutics, a Cambridge, MA, startup with a hybrid approach to the field.

PureTech reels in $55M to fund new biotech bets

Biotech startup machine PureTech has raised a $55 million round to fund the next stage of its evolution, recruiting some big thinkers to help it advance its stable of ventures and develop new technologies.

VC's biotech investing slips in Q3, but '14 still looks like a record-breaker

Last quarter biotech attracted a whopping $1.8 billion in new venture cash, the biggest quarter since 2005.

Canaan debuts $675M fund with an eye for biotech, med tech deals

Today Menlo Park, CA-based Canaan is rolling out a new fund, its 10th, with $675 million to invest in new companies--about a third of which will be devoted to biotech and healthcare.

DNAtrix pockets $20M to get its cancer-fighting virus into Phase III

DNAtrix, at work on viral treatment that selectively infects brain cancer cells, picked up $20 million in venture cash, funds the company said will help speed its candidate into late-stage study.

Pharma VCs cluster behind a brainchild of UK biotech pioneer Sir Greg Winter

While Atlas Venture was busy putting together a syndicate for Raze in Cambridge, MA, the venture group was also engaged in hatching a $32 million round across the Atlantic in the scientific hotbed of Cambridge, U.K. Atlas partnered with SV Life Sciences and three corporate venture arms--Novartis Venture Fund, GlaxoSmithKline's SR One and Astellas Venture Management--to back Bicycle Therapeutics.

Merck's VC unit invests in data security business

With report after report finding flaws in the data security practices of healthcare and life science organizations, Exostar has decided to accelerate its expansion into the sector. And the company has snagged funding from the Merck Global Health Innovation Fund to support its plans.

VC giant NEA recruits biotech vet Carol Gallagher to join its ranks of dealmakers

After more than 25 years in drug development that culminated in a corner office at Calistoga Pharmaceuticals, Carol Gallagher decamped for the venture world last year, and now she has accepted a position at New Enterprise Associates to help nurture the next generation of disruptive biotechs.